A Chinese research team has made significant advancements in the treatment of colorectal cancer, paving the way for a new milestone in the field of oncology treatment

A Chinese research team has made significant advancements in the treatment of colorectal cancer, paving the way for a new milestone in the field of oncology treatment

In recent years, natural killer (NK) cell immunotherapy has gained significant attention as a promising approach for treating solid tumors and malignant tumors of the blood system. NK cells, constituting 5% to 15% of lymphocyte circulation, are regarded as natural warriors against cancer, capable of directly identifying and killing cancer cells.

Umbilical cord blood NK cells bring new treatment options for colorectal cancer patients!

In a paper published in the journal “Human Gene Therapy” by a Chinese research team, researchers successfully expanded NK cells from umbilical cord blood (UCB) by utilizing membrane-bound interleukin (IL)-21, naming them eUCB-NK cells. Animal experiments demonstrated the robust in vivo anti-tumor activity of umbilical cord blood NK cells, suitable for late-stage colorectal cancer patients. Combining with bevacizumab can enhance NK cell infiltration, leading to improved therapeutic outcomes.

Moreover, CAR-NK therapy holds considerable promise. By genetically engineering chimeric antibodies into NK cells, they become capable of recognizing and destroying tumor cells. Safety and efficacy have been demonstrated in the treatment of colorectal cancer.

A study focusing on metastatic colorectal cancer revealed that local infusion of NKG2D mRNA CAR-NK cells led to rapid tumor reduction in patients, with no significant adverse events observed during the treatment process, introducing a novel strategy for tumor immunotherapy.

#ColorectalCancerTreatment #CancerResearch #NKCellTherapy #MedicalBreakthroughs #CancerTreatmentAdvances #TumorImmunotherapy #HealthInnovation #ScienceNews #OncologyProgress #eUCBNKCells

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

11 months ago CAR-T

A significant breakthrough in Chinese solid tumor CAR-T therapy, resulting in complete remission for pancreatic cancer patients.

Chinese pharmaceutical company SciCoMed announced a significant breakthrough in treating metastatic pancreatic cancer with its independently developed CAR-T cell therapy targeting Claudin18.2, known as CT041. Pancreatic cancer, often termed the “king of cancers,” presents a significant challenge with low survival rates. However, CT041’s two representative cases have garnered attention: two patients with refractory pancreatic cancer, who failed multiple lines of treatment, received CT041 therapy. The results showcased a substantial reduction in tumor lesions and, in some cases, complete disappearance, offering a glimmer of hope for pancreatic cancer patients.

In the case of a 58-year-old female patient, lung metastases significantly decreased post CT041 treatment. Similarly, a 75-year-old female patient achieved complete remission by the fourth week post-treatment, maintaining remission to date. These successful cases validate the remarkable efficacy of CT041 for refractory pancreatic cancer, sparking interest and anticipation among international experts.

Moreover, CT041 has garnered recognition for its efficacy in the field of digestive system tumors. As the world’s first CAR-T cell therapy targeting Claudin18.2, it demonstrates promising prospects in treating digestive system tumors. Research data illustrates that among 37 patients, 83.3% experienced tumor regression, with an objective response rate of 48.6%. Additionally, CT041 displayed significant effectiveness in late-stage gastric and pancreatic cancer patients, offering hope for future treatments.

The rapid development of CAR-T therapy in China involves over 20 companies contributing significantly. CT041’s success signifies China’s progress toward becoming a global leader in CAR-T therapy. Moving forward, scientists will continue efforts to enhance efficacy and reduce side effects, providing a ray of hope for more late-stage cancer patients.

#CARTTherapy #CancerTreatment #Immunotherap #CT041 #PancreaticCancer #CART #PancreaticCancer #MedicalBreakthrough #SciCoMed #TumorTreatment #ClinicalResearch #HealthInnovation